Skinvisible (SKVI) Capital Expenditures Growth (3y) (2022 - 2023)
Powered by 
Analysis
Skinvisible (SKVI) Capital Expenditures Growth (3y) (2022 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.02 Bn | 629.26 Bn | 17.26 Bn | 5.53% |
| 2 | AbbVie | 443.38 Bn | 436.81 Bn | 12.70 Bn | 21.85% |
| 3 | Merck | 368.22 Bn | 361.07 Bn | 12.21 Bn | -2.55% |
| 4 | Novartis Ag | 270.16 Bn | 262.47 Bn | 11.24 Bn | -12.57% |
| 5 | Pfizer | 158.63 Bn | 146.93 Bn | 10.94 Bn | -16.45% |
| 6 | Sanofi | 52.92 Bn | 45.54 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.49 Bn | 44.49 Bn | - | - |
| 8 | Incyte | 25.22 Bn | 20.69 Bn | 1.57 Bn | 19.16% |
| 9 | United Therapeutics | 21.17 Bn | 18.51 Bn | 683.80 Mn | 34.19% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -26.00% |
| Jun 30, 2023 | -13.90% |
| Mar 31, 2023 | -15.50% |
| Dec 31, 2022 | -72.81% |